220 related articles for article (PubMed ID: 23685222)
1. Measurement of urinary TGF-β1 in patients with diabetes mellitus and normal controls.
Tsapenko MV; Nwoko RE; Borland TM; Voskoboev NV; Pflueger A; Rule AD; Lieske JC
Clin Biochem; 2013 Oct; 46(15):1430-5. PubMed ID: 23685222
[TBL] [Abstract][Full Text] [Related]
2. The relationship between inflammation, endothelial dysfunction and proteinuria in patients with diabetic nephropathy.
Taslipinar A; Yaman H; Yilmaz MI; Demirbas S; Saglam M; Taslipinar MY; Agilli M; Kurt YG; Sonmez A; Azal O; Bolu E; Yenicesu M; Kutlu M
Scand J Clin Lab Invest; 2011 Nov; 71(7):606-12. PubMed ID: 21864054
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor beta 1 and monocyte chemoattractant protein-1 as prognostic markers of diabetic nephropathy.
Shaker OG; Sadik NA
Hum Exp Toxicol; 2013 Oct; 32(10):1089-96. PubMed ID: 23515495
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
Katavetin P; Eiam-Ong S; Suwanwalaikorn S
J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
[TBL] [Abstract][Full Text] [Related]
5. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Agarwal R; Siva S; Dunn SR; Sharma K
Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
[TBL] [Abstract][Full Text] [Related]
6. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
7. Gene polymorphism of transforming growth factor-β1 in Egyptian patients with type 2 diabetes and diabetic nephropathy.
El-Sherbini SM; Shahen SM; Mosaad YM; Abdelgawad MS; Talaat RM
Acta Biochim Biophys Sin (Shanghai); 2013 Apr; 45(4):330-8. PubMed ID: 23399816
[TBL] [Abstract][Full Text] [Related]
8. Urinary transforming growth factor-β1 in children with obstructive uropathy.
Zieg J; Blahova K; Seeman T; Bronsky J; Dvorakova H; Pechova M; Janda J; Matousovic K
Nephrology (Carlton); 2011 Aug; 16(6):595-8. PubMed ID: 21382126
[TBL] [Abstract][Full Text] [Related]
9. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
[TBL] [Abstract][Full Text] [Related]
10. Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy.
Wu CC; Chen JS; Lu KC; Chen CC; Lin SH; Chu P; Sytwu HK; Lin YF
Clin Chim Acta; 2010 May; 411(9-10):700-4. PubMed ID: 20138168
[TBL] [Abstract][Full Text] [Related]
11. [Urinary excretion of fibrogenic and antifibrotic growth factors in type 1 diabetic patients: the interrelationship with diabetic nephropathy].
Bondar' IA; Klimontov VV; Parfent'eva EM; Romanov VV; Nadeev AP
Ter Arkh; 2012; 84(6):36-40. PubMed ID: 22997916
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta 1 in Balkan endemic nephropathy.
Dukanović L; Lezaić V; Miljković D; Momcilović M; Bukvić D; Marić I; Miljković Z; Marinković J; Mostarica-Stojković M
Nephron Clin Pract; 2009; 111(2):c127-32. PubMed ID: 19147994
[TBL] [Abstract][Full Text] [Related]
13. Identification of urinary soluble E-cadherin as a novel biomarker for diabetic nephropathy.
Jiang H; Guan G; Zhang R; Liu G; Cheng J; Hou X; Cui Y
Diabetes Metab Res Rev; 2009 Mar; 25(3):232-41. PubMed ID: 19177462
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta 1 in diabetic nephropathy.
Metwally SS; Mosaad YM; Nassr AA; Zaki OM
Egypt J Immunol; 2005; 12(1):103-12. PubMed ID: 16734145
[TBL] [Abstract][Full Text] [Related]
15. [Cytokines in noninvasive diagnostics of diabetic nephropathy progression].
Senatorski G; Paczek L; Kropiewnicka E; Bartłomiejczyk I
Pol Merkur Lekarski; 2002 Nov; 13 Suppl 1():28-32. PubMed ID: 12621778
[TBL] [Abstract][Full Text] [Related]
16. [Urine excretion of a monocytic chemotaxic protein-1 and a transforming growth factor beta1 as an indicator of chronic glomerulonephritis progression].
Bobkova IN; Chebotareva NV; Kozlovskaia LV; Varshavskiĭ VA; Golitsyna EP
Ter Arkh; 2006; 78(5):9-14. PubMed ID: 16889042
[TBL] [Abstract][Full Text] [Related]
17. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus.
Cha DR; Kim IS; Kang YS; Han SY; Han KH; Shin C; Ji YH; Kim NH
Diabet Med; 2005 Jan; 22(1):14-20. PubMed ID: 15606685
[TBL] [Abstract][Full Text] [Related]
18. Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.
Bertoluci MC; Uebel D; Schmidt A; Thomazelli FC; Oliveira FR; Schmid H
Diabetes Res Clin Pract; 2006 Jun; 72(3):258-64. PubMed ID: 16414143
[TBL] [Abstract][Full Text] [Related]
19. Urinary MCP-1 and RBP: independent predictors of renal outcome in macroalbuminuric diabetic nephropathy.
Titan SM; Vieira JM; Dominguez WV; Moreira SR; Pereira AB; Barros RT; Zatz R
J Diabetes Complications; 2012; 26(6):546-53. PubMed ID: 22981148
[TBL] [Abstract][Full Text] [Related]
20. [Infect of pingshen decoction on serum HGF, Cys C and TGF-beta1 diabetic nephropathy in early stage].
Bao HL; Ye SH; Lou SX; Lu XW; Zhou XF
Zhongguo Zhong Yao Za Zhi; 2014 Mar; 39(6):1128-31. PubMed ID: 24956865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
